205 related articles for article (PubMed ID: 31050810)
1. Treatment of Philadelphia-negative myeloproliferative neoplasms in accelerated/blastic phase with azacytidine. Clinical results and identification of prognostic factors.
Andriani A; Elli E; Trapè G; Villivà N; Fianchi L; Di Veroli A; Niscola P; Centra A; Anaclerico B; Montanaro G; Martini V; Aroldi A; Carmosino I; Voso MT; Breccia M; Montanaro M; Foà R; Latagliata R
Hematol Oncol; 2019 Aug; 37(3):291-295. PubMed ID: 31050810
[TBL] [Abstract][Full Text] [Related]
2. Azacytidine for the treatment of retrospective analysis from the Gruppo Laziale for the study of Ph-negative MPN.
Andriani A; Montanaro M; Voso MT; Villivà N; Ciccone F; Andrizzi C; De Gregoris C; Di Veroli A; Maurillo L; Alimena G; Latagliata R
Leuk Res; 2015 Aug; 39(8):801-4. PubMed ID: 26065981
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase.
Badar T; Kantarjian HM; Ravandi F; Jabbour E; Borthakur G; Cortes JE; Pemmaraju N; Pierce SR; Newberry KJ; Daver N; Verstovsek S
Leuk Res; 2015 Sep; 39(9):950-6. PubMed ID: 26183878
[TBL] [Abstract][Full Text] [Related]
4. [Clinical characteristics and prognostic factors of patients with Philadelphia-negative myeloproliferative neoplasm accelerated/blast phase].
Yan X; Qin TJ; Li B; Qu SQ; Pan LJ; Li FH; Liu NN; Xiao ZJ; Xu ZF
Zhonghua Xue Ye Xue Za Zhi; 2023 Apr; 44(4):276-283. PubMed ID: 37356995
[No Abstract] [Full Text] [Related]
5. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).
Thepot S; Itzykson R; Seegers V; Raffoux E; Quesnel B; Chait Y; Sorin L; Dreyfus F; Cluzeau T; Delaunay J; Sanhes L; Eclache V; Dartigeas C; Turlure P; Harel S; Salanoubat C; Kiladjian JJ; Fenaux P; Adès L;
Blood; 2010 Nov; 116(19):3735-42. PubMed ID: 20664061
[TBL] [Abstract][Full Text] [Related]
6. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
Gangat N; Guglielmelli P; Szuber N; Begna KH; Patnaik MM; Litzow MR; Al-Kali A; Foran JM; Palmer JM; Alkhateeb H; Elliott MA; Hanson CA; Pardanani A; Mannelli F; Vannucchi AM; Tefferi A
Am J Hematol; 2021 Jul; 96(7):781-789. PubMed ID: 33844862
[TBL] [Abstract][Full Text] [Related]
7. Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the 'real life' setting: A single center observational study.
Papageorgiou SG; Vasilatou D; Kontos CK; Foukas P; Kefala M; Ioannidou ED; Bouchla A; Bazani E; Dimitriadis G; Pappa V
Hematology; 2016 Jan; 21(1):34-41. PubMed ID: 26218077
[TBL] [Abstract][Full Text] [Related]
8. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms.
Stein BL; Tiu RV
J Interferon Cytokine Res; 2013 Apr; 33(4):145-53. PubMed ID: 23570380
[TBL] [Abstract][Full Text] [Related]
9. Clinical Benefit Derived from Decitabine Therapy for Advanced Phases of Myeloproliferative Neoplasms.
Zhou S; Tremblay D; Hoffman R; Kremyanskaya M; Najfeld V; Li L; Moshier E; Mascarenhas J
Acta Haematol; 2021; 144(1):48-57. PubMed ID: 32160610
[TBL] [Abstract][Full Text] [Related]
10. Myeloproliferative neoplasia: a review of clinical criteria and treatment.
Koopmans SM; van Marion AM; Schouten HC
Neth J Med; 2012 May; 70(4):159-67. PubMed ID: 22641623
[TBL] [Abstract][Full Text] [Related]
11. Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia.
Reda G; Riva M; Fattizzo B; Cassin R; Giannarelli D; Pennisi M; Freyrie A; Cairoli R; Molteni A; Cortelezzi A
Semin Hematol; 2018 Oct; 55(4):202-208. PubMed ID: 30502848
[TBL] [Abstract][Full Text] [Related]
12. Combination of azacitidine, venetoclax and ruxolitinib in blast phase myeloproliferative neoplasms.
Systchenko T; Chomel JC; Gallego-Hernanz P; Moya N; Desmier D; Maillard N; Bobin A; Vonfeld M; Gardeney H; Cayssials E E; Torregrosa J
Br J Haematol; 2023 Jul; 202(2):284-288. PubMed ID: 37183377
[TBL] [Abstract][Full Text] [Related]
13. Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia.
Kantarjian HM; O'Brien S; Cortes J; Giles FJ; Faderl S; Issa JP; Garcia-Manero G; Rios MB; Shan J; Andreeff M; Keating M; Talpaz M
Cancer; 2003 Aug; 98(3):522-8. PubMed ID: 12879469
[TBL] [Abstract][Full Text] [Related]
14. 5-azacitidine reversing "spent" phase polycythemia vera back to proliferative phase and need for phlebotomy.
Lerner J; Michel M; Dasanu CA
J Oncol Pharm Pract; 2020 Jul; 26(5):1285-1288. PubMed ID: 32054413
[TBL] [Abstract][Full Text] [Related]
15. Essential differences in clinical and bone marrow features in BCR/ABL-positive thrombocythemia compared to thrombocythemia in the BCR/ABL-negative myeloproliferative neoplasms essential thrombocythemia and polycythemia vera.
Michiels JJ; Pich A; De Raeve H; Gadisseur A
Acta Haematol; 2015; 133(1):52-5. PubMed ID: 25116159
[No Abstract] [Full Text] [Related]
16. Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms.
Soyer N; Haznedaroğlu İC; Cömert M; Çekdemir D; Yılmaz M; Ünal A; Çağlıyan G; Bilgir O; İlhan O; Özdemirkıran F; Kaya E; Şahin F; Vural F; Saydam G
Turk J Haematol; 2017 Mar; 34(1):27-33. PubMed ID: 27094252
[TBL] [Abstract][Full Text] [Related]
17. Results of decitabine therapy in the accelerated and blastic phases of chronic myelogenous leukemia.
Kantarjian HM; O'Brien SM; Keating M; Beran M; Estey E; Giralt S; Kornblau S; Rios MB; de Vos D; Talpaz M
Leukemia; 1997 Oct; 11(10):1617-20. PubMed ID: 9324279
[TBL] [Abstract][Full Text] [Related]
18. Association of TNF polymorphisms with JAK2 (V617F) myeloproliferative neoplasms in Brazilian patients.
Macedo LC; de Cesare Quintero F; Pagliari-E-Silva S; Pagnano KB; Rodrigues C; de Alencar JB; Sell AM; Visentainer JE
Blood Cells Mol Dis; 2016 Mar; 57():54-7. PubMed ID: 26852656
[TBL] [Abstract][Full Text] [Related]
19. The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study.
Tombak A; Uçar MA; Akdeniz A; Tiftik EN; Gören Şahin D; Akay OM; Yıldırım M; Nevruz O; Kis C; Gürkan E; Solmaz ŞM; Özcan MA; Yıldırım R; Berber İ; Erkurt MA; Fıratlı Tuğlular T; Tarkun P; Yavaşoğlu İ; Doğu MH; Sarı İ; Merter M; Özcan M; Yıldızhan E; Kaynar L; Mehtap Ö; Uysal A; Şahin F; Salim O; Sungur MA
Turk J Haematol; 2016 Dec; 33(4):273-280. PubMed ID: 27095141
[TBL] [Abstract][Full Text] [Related]
20. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
